NCT03113825 - Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 5, 2017

Primary Completion Date

April 8, 2020

Study Completion Date

November 18, 2020

Conditions

Primary Invasive Malignant Neoplasm of Female BreastCarcinoma BreastBreast Cancer FemaleCarcinoma, Ductal, BreastStage II Breast CancerStage I Breast CancerStage III Breast Cancer

Interventions

DEVICE

Investigational Imaging device

Fluorescence imaging of the of the primary tumor specimen, any secondary breast specimens, and lymph nodes will be performed.

DRUG

AVB-620

AVB-620 will be administered IV before the surgical procedure.

Trial Locations (13)

10461

Montefiore Einstein Center for Cancer Care, The Bronx

14263

Roswell Park Cancer Institute, Buffalo

29401

Roper St. Francis Hospital, Charleston

32224

Mayo Clinic Jacksonville -- Center for Breast Health, Jacksonville

33612

Moffitt Cancer Center, Tampa

43210

Ohio State University, James Cancer Center, Columbus

44106

University Hospitals Cleveland Medical Center, Cleveland

48073

William Beaumont Hospital, Royal Oak

60010

Advocate Good Shepherd Hospital, Barrington

89102

UNLV School of Medicine, Las Vegas

92093

UCSD, San Diego

98104

Swedish Cancer Institute, Seattle

200010

Medstar Washington Hospital, Washington D.C.